



**Date: 7 May 2018**

**Sydney, Australia**

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966 123

**Registered Office**  
and

**Operational Office:**

Suite 3, Level 4

828 Pacific Highway

Gordon NSW 2072

Australia

**Board of Directors**

**Mr Peter Marks**

Chairman

Non-Executive

Director

**Dr Graham Kelly**

Chief Executive Officer

Managing Director

**Dr Ian Dixon**

Non-Executive

Director

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

## **NOXOPHARM CEO INTERVIEW UPDATES THE COMPANY'S CURRENT RESEARCH & DEVELOPMENT PROGRAM**

Sydney, 7 May 2018: Noxopharm (ASX: NOX) today releases the third of a series of 3 interviews with CEO, Dr Graham Kelly. The interviews with the Finance News Network provide an update on each of the 3 general NOX66 programs:

- NOX66 as an enhancer of radiotherapy
- NOX66 as an enhancer of the efficacy and safety of chemotherapy
- The supporting Research & Development program.

The third interview in this series updates the Company's current Research and Development (R & D) program.

This interview can be found by visiting the Noxopharm website at [www.noxopharm.com](http://www.noxopharm.com) and going to the **Investors** Section/ **Presentations** page.

.....

### **About NOX66**

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour. The radio-enhancing effects of idronoxil are believed to involve at least 2 functions: (i) its ability to block DNA repair mechanisms (PARP-1, topoisomerases 1 and 2); (ii) its immune-enhancing effects, stimulating the activity of human natural killer (NK) cells.

### **About Noxopharm**

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. NOX66 is the first pipeline product.

**About Nyrada Inc**

Nyrada Inc is a Noxopharm majority-owned subsidiary company formed for the purpose of housing non-oncology drug development intellectual property (IP). Nyrada is a US-registered company based in New York. Its purpose is to house non-oncology IP that is outside Noxopharm's primary focus on oncology drug development and which in the Noxopharm Board's view, represents the best means of creating value for Noxopharm shareholders for non-core IP.

Nyrada has commenced with 3 drug assets across 4 main clinical indications. Each asset is pre-clinical. Nyrada proposes to bring each asset into the clinic.

**Investor & Corporate Enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary:**

David Franks

T: +61 2 9299 9690

E: [dfranks@fa.com.au](mailto:dfranks@fa.com.au)

[www.noxopharm.com](http://www.noxopharm.com)

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.